CAR T-Cell Therapy Sends Refractory Rheumatoid Arthritis Into Remission in Early Trial
4 of 6 hard-to-treat RA patients showed major disease improvement, with 3 achieving remission after CAR T-cell therapy.
Summary
A small but promising phase I trial has shown that CAR T-cell therapy — best known as a cancer treatment — may work against severe, treatment-resistant rheumatoid arthritis. Six patients who had failed three to eight prior biologic drugs received engineered immune cells targeting B cells. Four achieved major reductions in disease activity, three reached clinical remission by 36 weeks, and all six saw drops in the autoantibodies that drive joint damage. This is notable because rheumatoid arthritis was not traditionally considered a B-cell disease, but the seropositive subtype does involve these immune cells. The results, presented at a major rheumatology conference, suggest CAR T-cell therapy could eventually offer a reset for patients with no remaining treatment options.
Detailed Summary
Rheumatoid arthritis affects millions worldwide, causing progressive joint destruction, pain, and disability. For a subset of patients, no available drug provides lasting relief. A new phase I trial presented at the European Alliance of Associations for Rheumatology annual meeting offers a potential breakthrough for this group using CAR T-cell therapy — a technology originally developed to fight blood cancers.
In the trial, six patients with severe, seropositive RA who had already failed three to eight biologic or targeted therapies received autologous CAR T-cells engineered to eliminate B cells. These patients had disease durations up to 24 years and high disease activity scores at baseline. All six underwent lymphodepletion before receiving the engineered cells, and prior disease-modifying drugs were stopped.
By week 36, five of the six patients achieved at least an ACR20 response — a 20% reduction in symptom severity — and four reached ACR70, meaning a 70% reduction. Three patients entered clinical remission. Autoantibody levels, including anti-citrullinated protein antibodies and rheumatoid factor, dropped markedly across all six participants. Safety data aligned with what has been observed in CAR T-cell trials for lupus and other autoimmune diseases.
One concern emerged: a patient followed to 52 weeks showed a partial rebound in rheumatoid factor after initial clearance, hinting that durability may be a challenge for some. Researchers could not identify baseline factors that predicted who would respond strongly versus modestly, which complicates future patient selection.
The phase II randomized portion of the trial is now enrolling, with 10 patients split between CAR T-cell therapy and placebo. While the sample size remains very small and long-term follow-up is limited, these early findings suggest that immune resetting via CAR T-cell therapy could become a viable strategy for the most treatment-resistant autoimmune diseases, with potential implications far beyond oncology.
Key Findings
- 3 of 6 severe RA patients achieved clinical remission by 36 weeks after CAR T-cell therapy
- 4 of 6 patients achieved ACR70 response — a 70% reduction in disease severity
- All 6 patients showed significant drops in disease-driving autoantibodies (ACPA and rheumatoid factor)
- One patient showed partial autoantibody rebound at 52 weeks, raising durability questions
- Safety profile matched prior CAR T-cell trials in other autoimmune diseases like lupus
Methodology
This is a conference news report from MedPage Today covering phase I results of an ongoing phase I/II clinical trial presented at EULAR 2026. The source is a credible medical news outlet. Evidence is preliminary, based on six patients with no control group in the phase I portion.
Study Limitations
Only six patients were treated in phase I with no control arm, making efficacy conclusions very preliminary. Long-term durability is uncertain given one patient's autoantibody rebound at 52 weeks. Full peer-reviewed publication has not yet been cited; conference data should be verified against the final manuscript.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.